Business Wire

CA-C3.AI

9.11.2021 15:02:39 CET | Business Wire | Press release

Share
Shell Offers New AI-Powered Applications Through Open AI Energy Initiative

C3 AI (NYSE:AI) and Shell (NYSE:RDS) today announced three new Shell products that will be available through the Open AI Initiative (OAI), an open ecosystem of artificial intelligence (AI)-based solutions for the energy and process industries.

The OAI, launched by C3 AI, Shell, Baker Hughes and Microsoft in February 2021, provides an open framework for energy operators, service & equipment providers, and independent software vendors to offer interoperable solutions, powered by the BHC3 AI Suite and Microsoft Azure. The three new OAI products – Shell Process Optimiser for LNG, Shell Corrosion Advanced Risk Modelling and Analytics, and Shell Autonomous Integrity Recognition – target use cases that will solve key challenges for businesses in the energy industry. By using Shell’s proven domain-specific AI applications built on BHC3’s scalable AI application development platform and SaaS applications, businesses can rapidly move past data discovery and cleaning to application deployment and realization of value in critical business areas.

Details on the new offerings are outlined below:

  • Shell Process Optimiser for LNG – The application marries state-of-the-art LNG process engineering and technology with data analytics to enhance asset production by helping asset engineers close the gap between current and optimal production (“gap to potential”) by changing key identified operating conditions as optimization levers. The application integrates sensor information, such as pressure, temperature, and flow rate to calculate the optimum setting using custom-built asset machine learning models. It reveals unknown correlations and sweet spots, and derives the best suitable strategies as optimization know-how. The application, capable of handling operational, economic, and engineering constraints, Shell Process Optimiser for LNG generates actionable insights that can be integrated and brought into the continuous closed loop process control layer for sustained benefits realisation.
  • Shell Corrosion Advanced Risk Modelling and Analytics – The application makes use of novel data analytics techniques to predict internal corrosion and erosion to better prioritize and target inspection and maintenance activities. By using a variety of collected site data, and with the help of artificial intelligence, the software provides new insights to predict corrosion and erosion and identify degradation before leaks happen. By using this solution, operators can lower inspection costs and HSSE risk, minimise cost of related leaks, and safely push production to the limit. Additionally, Shell Corrosion Advanced Risk Modelling and Analytics reduces the need for manual, tedious field inspections, resulting in significant time and cost savings.
  • Shell Autonomous Integrity Recognition – The application allows inspectors to quickly and easily make use of automated image capture and evaluation to support execution of external integrity inspections. By processing data in the cloud coming from inspections carried out with handheld devices, drones and robots, the solution enables inspectors to objectively evaluate issues, identify items that have been overlooked, reduce the time needed at the desk generating reports, and improve inputs to maintenance planning. Shell Autonomous Integrity Recognition application allows users to identify and classify external corrosion and insulation issues with Machine Vision to reduce leakages. By using this, users can improve the quality, efficiency, and standardization of visual inspections.

These products expand the portfolio of solutions available to OAI subscribers and help accelerate the adoption of enterprise AI in the energy and process industries.

“Previously, there was no framework for Oil and Gas operators to subscribe to proven AI and advanced analytic solutions offered by other operators,” said C3 AI CEO Thomas M. Siebel. “By bringing more solutions built on the BHC3 AI Suite to the OAI, Shell is demonstrating market leadership and establishing the OAI as a one-of-a-kind model of collaboration.”

These applications also broaden the focus areas of the OAI offerings from asset and system reliability to facility and plant optimization and asset integrity, adding to an expanding portfolio of highly differentiated, domain-specific and proven AI applications and modules that are interoperable. These applications can be deployed together to realize business value and create scalable, futureproof reference architectures.

“The products announced today have already been deployed at Shell and have been proven to either create operational efficiencies and savings or generate additional revenue and opportunity,” said Dan Jeavons, Vice President Computational Science and Digital Innovation at Shell. “As more products are added to the growing OAI eco-system, we look forward to working with C3 AI, Baker Hughes, and the other ecosystem partners to build the next-generation platform for the future energy system.”

About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI® delivers a family of fully integrated products: C3 AI® Suite , an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications , a portfolio of industry-specific SaaS AI applications; C3 AI CRM , a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina , a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai .

About Royal Dutch Shell plc
Royal Dutch Shell plc is incorporated in England and Wales‚ has its headquarters in The Hague and is listed on the London‚ Amsterdam‚ and New York stock exchanges. Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. For further information, visit www.shell.com . The companies in which Royal Dutch Shell plc directly and indirectly owns investments are separate legal entities. In this document “Shell” is sometimes used for convenience where references are made to Royal Dutch Shell plc and its subsidiaries in general.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye